← Evidence library

BIB_163

Kirkwood JM et al. Adjuvant nivolumab vs placebo in resected stage IIB/IIC melanoma (CheckMate-76K): phase 3 RCT. Nature Medicine 2024. n=790; RFS HR 0.42 at 16mo. Companion to KEYNOTE-716. [Tasks: 17, 18] Tier: 1 Grade: A Retrieved: 2026-05-07

Evidence grade

A

Tier

1

Cited by tasks

17, 18

Identifiers

—

Full extracted findings & patient-implication analysis: bibliography/BIB_163/findings.md (research corpus). This page is a short context summary — not individualised medical advice.